arrow
D

David de Semir

caris life sciences, phoenix, az 85040, usa
H指数:19
被引数:1,391

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate Cancer

GR-LEDGF/p75-HSP27轴在前列腺癌中促进了恩杂鲁胺和多西他赛之间的交叉耐药性。

2025-10-090
OAAI
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade

靶向对免疫检查点阻断耐药的黑色素瘤预临床模型的组合疗法方案

2025-09-160
OA
Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to Docetaxel

抑制线粒体相关蛋白MAGMAS可重新使耐药性前列腺癌细胞对多西他赛敏感

CANCERS
IF4.4
2025-04-300
OA
Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
2023-07-130
OA
Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience
2022-11-043
OA
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach
2021-08-0123
OAAI
PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex
2020-04-0926
OAAI
Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies
2019-12-2016
OAAI
PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer
2018-06-0419
OAAI